Cogstate Doubles Contract Sales and Boosts Dividend on Record FY26 Performance

Record Contract Sales Propel Revenue and Profit Growth

Cogstate Ltd (ASX:CGS) has delivered a standout FY26, with clinical trial sales contracts more than doubling to US$89 million, up 116% on the prior year. This surge underpinned a 15% increase in total revenue to US$60.9 million and a 15.9% rise in profit before tax to US$16.1 million. The company’s clinical trials segment, which accounts for the lion’s share of revenue, grew 15.4% to US$58.4 million, while the smaller healthcare segment remained steady at US$2.5 million.

Gross profit reached US$35.4 million, representing a 58% margin for the year, with a notable margin expansion in the second half where gross margin hit 62% and EBITDA margin rose to 35%. Cogstate’s disciplined cost management and capital-light model delivered an EBIT margin increase to 25%, highlighting operational leverage as the business scales.

Diversified Portfolio and Expanding Pipeline Mitigate Concentration Risk

The company’s clinical trials portfolio expanded to 171 active trials, up 55% year-on-year, spanning all drug development phases. Diversification beyond Alzheimer’s disease continues, with mood and psychiatric disorders, sleep, rare diseases, and neurological conditions now accounting for 77% of new contract value. Alzheimer’s disease contracts contributed 23%, down from previous years, reflecting Cogstate’s successful expansion into broader CNS indications.

This diversification reduces reliance on any single therapeutic area or customer, with the largest client representing 42% of revenue. Strategic partnerships with clinical trial technology platforms like Medidata have been instrumental in broadening Cogstate’s market reach, driving approximately 40% of new sales contract value in FY26 through partner-led channels.

Strong Contracted Revenue Base Provides Earnings Visibility

Cogstate enters FY27 with a record contracted future revenue backlog of US$118.5 million, up 32% from FY25. Of this, US$48.3 million is expected to be recognised as revenue in FY27, a 54% increase on the prior year. The clinical trials contracted revenue backlog alone stands at US$107.1 million, providing a solid foundation for continued growth.

Management notes that while revenue growth depends on the timing and conversion of new contracts, the strong starting position and positive market conditions support an optimistic outlook. Consistent with recent years, FY27 is expected to show a second half earnings bias.

Investing in AI and Technology to Scale Operations and Margins

FY26 saw continued investment in AI-enabled products and operating platform capabilities, including AI Rater Training and AI Central Monitoring, which are now embedded in Cogstate’s clinical trial toolkit. These initiatives aim to enhance data quality, automate workflows, and improve operational efficiency, supporting scalability as the number of active trials grows.

The company plans a two-year build-out of AI-powered workflow orchestration and system integration across FY27 and FY28. This technology-driven operating system is designed to limit headcount growth relative to revenue, expand gross margins, and strengthen Cogstate’s differentiation in the CNS clinical trials market.

Capital Management and Shareholder Returns

Cogstate’s disciplined capital allocation framework balances technology investment, selective growth initiatives, and shareholder returns. The company ended FY26 with a healthy cash balance of US$34.8 million and no debt.

The Board declared a fully franked final dividend of A$0.04 per share, doubling the prior year’s payout and reflecting confidence in the company’s sustainable earnings and cash flow. The ongoing on-market share buy-back program has repurchased over 12 million shares since FY23, representing more than 6% of issued shares, supporting shareholder value amid strong share price performance.

Executive Remuneration Reflects Strong Performance

Cogstate’s FY26 remuneration framework aligns executive pay with company performance, combining fixed salary, short-term cash incentives, and long-term performance rights tied to earnings per share and revenue growth. The CEO’s short-term incentive was awarded at 83% of maximum, reflecting strong financial and strategic achievements. Non-executive director fees increased on average by 16% following committee restructuring, supporting enhanced governance as the company scales.

These remuneration outcomes underscore the Board’s commitment to linking pay with sustainable growth and shareholder returns.